Skye Bioscience, Inc. 8-K

What Happened
On March 10, 2026, Skye Bioscience, Inc. (Skye) announced and filed a press release reporting its financial results for the fourth quarter and full year ended December 31, 2025. The full text of that press release is attached to the Current Report on Form 8‑K as Exhibit 99.1.

Key Details

• The Form 8‑K was filed on March 10, 2026 and reports results for the period ended December 31, 2025.
• Press release containing the reported results is attached as Exhibit 99.1 to the filing.
• An interactive XBRL cover page (Exhibit 104) is included with the filing.
• The filing notes, per Form 8‑K General Instruction B.2, that the information (including the press release) is furnished, not “filed,” and therefore is not subject to Section 18 liability or automatically incorporated by reference into other securities filings.

Why It Matters
This filing signals Skye’s most recent operating and financial performance for Q4 and full year 2025 and provides the company’s current results for investors to review. The attached press release is the primary source for the detailed figures (revenue, expenses, cash position, or other metrics), so investors should read Exhibit 99.1 and watch for related filings (e.g., a Form 10‑K or earnings presentation) for full financial detail and discussion. Note the company’s legal disclaimer that the press release is furnished rather than filed, which affects how the information is treated under securities law.